Nov 27 (Reuters) - Mesoblast Ltd MSB.AX :
* Mesoblast's Japan licensee receives pricing for Temcell HS inj. for
treatment of acute graft versus host disease
* Says reimbursement for Temcell has been authorized by NHI at ¥868,680
(A$9,767 / US$7,079) per bag of 72 million cells
* Source text for Eikon urn:newsml:reuters.com:*:nGNXMEQCJa
* Further company coverage MSB.AX